Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year Business live – latest updates GSK’s new boss, Luke Miels , has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two late-stage medications. The FTSE 100 company is increasing its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech company that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share in cash.
Search
Congressional trades, bills, prediction markets, hearings, and intelligence signals. Signal search supports: AND OR "exact phrase" -exclude
Congress & Markets2 trades · 0 bills · 0 markets · 0 hearings
Found 5 results across trades (2), signals (3)
Congressional Trades(2)
GSK—·Marjorie Taylor Mrs Greene(R · GA)·buy·Nov 27, 2024
GSK—·Marjorie Taylor Mrs Greene(R · GA)·buy·Sep 4, 2024